SABSSAB Biotherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of SAB Biotherapeutics, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SABSEsta | $294M#8 | 13.5x#4 | 1.4x#5 | — | -100.0%#10 | 138.9%#1 | — | 6.2%#1 | — | — | -0.6%#7 | — |
| SRZN | $367M#1 | — | — | 105.5x#9 | -67.4%#8 | -280.8%#13 | -1210.6%#7 | — | — | — | 123.0%#2 | — |
| KYTX | $320M#4 | — | 1.9x#8 | — | — | -26.5%#9 | — | -97.4%#10 | -107.1%#3 | — | -18.3%#8 | — |
| XFOR | $316M#5 | 2.2x#2 | 2.0x#9 | 9.0x#4 | 1273.2%#2 | -111.5%#11 | -247.4%#4 | -50.9%#6 | -582.0%#4 | — | -19.2%#9 | — |
| AGEN | $312M#6 | 2.3x#3 | — | 2.7x#1 | 10.4%#4 | 98.7%#2 | -17.7%#2 | — | — | — | 86.1%#3 | — |
| IPSC | $305M#7 | — | 1.3x#4 | 2.8x#2 | 1556.8%#1 | 92.4%#3 | -15.8%#1 | -4.1%#3 | -9.3%#1 | — | 195.5%#1 | — |
| EIKN | $326M#2 | — | 0.7x#1 | — | — | — | — | 0.0%#2 | — | — | — | — |
| SCTX | $323M#3 | — | — | — | — | — | — | — | — | — | — | — |
| OCGN | $290M#9 | — | — | 65.8x#8 | 8.8%#5 | -25.9%#8 | -1425.7%#8 | — | — | — | -40.0%#11 | — |
| LXEO | $265M#10 | — | 1.1x#2 | 405.8x#10 | — | -1.7%#5 | -16706.0%#10 | -42.5%#5 | — | — | -61.3%#14 | — |
| LCTX | $260M#11 | — | 4.3x#11 | 17.9x#6 | 53.2%#3 | -241.4%#12 | -251.6%#5 | -104.3%#11 | — | — | -43.3%#12 | — |
| FATE | $248M#13 | — | 1.6x#6 | 37.3x#7 | -51.2%#7 | 26.8%#4 | -2222.4%#9 | -88.8%#9 | -102.3%#2 | — | 73.2%#4 | — |
| ALEC | $251M#12 | — | — | 11.9x#5 | -79.1%#9 | -20.2%#7 | -741.3%#6 | — | — | — | 67.9%#5 | — |
| CABA | $242M#14 | — | 1.2x#3 | — | — | -44.9%#10 | — | -79.7%#7 | — | — | -47.0%#13 | — |
| PALI | $218M#15 | 1.9x#1 | 1.8x#7 | — | — | -16.2%#6 | — | -13.8%#4 | — | — | -31.9%#10 | — |
| DTIL | $218M#16 | 24.3x#5 | 4.2x#10 | 6.4x#3 | -50.1%#6 | -738.0%#14 | -152.2%#3 | -88.3%#8 | — | — | 16.7%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice